-- New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2018-- Foundation Medicine , today announced the publication of the results of a large study demonstrating

Basel, 31 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all

CAMBRIDGE, Mass. & REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 18, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc . announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S. Patent No. 9,340,830.

Basel, 2 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the

Together, the companies will leverage expertise  in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer Merger focuses on driving ubiquity of Foundation Medicine's high quality comprehensive genomic profiling (CGP) testing and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences: Goldman Sachs Annual Healthcare Conference on Tuesday, June 12, 2018 at 1:20 p.m. P.T.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated from its comprehensive genomic profiling (CGP) assays will be presented at the American Society of Clinical Oncology ( ASCO ) Annual Meeting from June 1-5, 2018 in

-- Pan-Cancer MSI Companion Diagnostic for KEYTRUDA ® (pembrolizumab) Planned for Inclusion on FoundationOne CDx™-- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 24, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services (CMS) approved new Advanced Diagnostic Laboratory Test (ADLT) status for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2018-- Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: Posted revenue of $52.8 million, 101% year-over-year growth; Reported 21,861 clinical